Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mycobacterium tuberculosis

ABSTRACT: Seq&Treal Phase II clinical trial results

PROVIDER: PRJNA1160005 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR30673100_1.fastq.gz	Fastqsanger.gz
	SRR30673100_2.fastq.gz	Fastqsanger.gz
	SRR30673200_1.fastq.gz	Fastqsanger.gz
	SRR30673200_2.fastq.gz	Fastqsanger.gz
	SRR30673300_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 3686

Similar Datasets

Project description:Gepotidacin microbiome analysis from Phase II clinical trial

| PRJNA630295 | ENA

Mycobacterium tuberculosis

Project description:WGS and pDST data from the XDR clinical trial of FIND

| PRJNA1087582 | ENA

Genomic testing in early localized prostate cancer may define subsets of African Americans with aggressive disease—a prospective study

Project description:Gene expression study of the VANDAAM Phase II clinical trial

2022-07-29 | GSE209954 | GEO

AtezoTRIBE

Project description:Microbiome samples from the AtezoTRIBE phase-II clinical trial

| PRJEB72523 | ENA

Circulating microRNA analysis in a prospective co-clinical trial identifies biomarker of response and mechanisms of resistance to regorafenib in colorectal cancer

Project description:MicroRNA profiling was performed on baseline bloods using the NanoString nCounter platform in a serial liquid biopsies obtained at baseline in chemo-refractory mCRC patients treated with regorafenib in a phase II clinical trial (PROSPECT-R n=40; NCT03010722).

2024-01-25 | GSE248663 | GEO

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Project description:The pre-clinical efficacy and safety data support the initiation of a phase I/II clinical trial for β-globin gene correction in patient-derived hematopoietic stem cells for the treatment of sickle cell disease.

2021-05-16 | GSE163912 | GEO

8b1e06b6-f298-4d8d-afbc-505c8c1c1555 - samples

Project description:Matrices of TPM-normalized counts from RNAseq data for the three phase II clinical trials (IMvigor210, POPLAR, IMmotion150) and the phase I clinical trial PCD4989g.

| EGAD00001006741 | EGA

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Project description:High-througput transcriptome analysis by RNA-seq of multiple myeloma tumor samples (CD138+ cells) in subjects treated with pomalidomide, daily low dose oral cyclophosphamide and dexamethasone in the context of a phase II clinical trial. Samples were collected at baseline as a correlative study to determine whether gene expression profiles could distinguish patients with (un)favorable response to treatment.

2019-10-11 | GSE138717 | GEO

Mycobacterium tuberculosis transcriptional response to small molecule

Project description:We applied RNAseq (Nextseq) technology to study mechanism of action of nitro-containing heterocycle antitubercular JSF-2019, with des-nitro JSF-2026 as control. Briefly, mid-log phase (OD = 0.3) M. tuberculosis culture was treated by 10x MIC of each compound in biological quadruplicates followed by mRNA extraction and RNAseq analysis. We find that JSF-2019 and pretomanid as intracellular NO• donors exhibited distinct transcriptional patterns comparing to extracellular iNOS inducer such as DETA/NO, therefore it suggests distinguished mechanisms of action between intracellular vs. extracellular NO• donors. We also observed that JSF-2019 upregulated a subset of FAS-II genes similar to isoniazid, indicating JSF-2019 inhibits intracellular mycolic acid biosynthesis.

2019-02-19 | GSE126718 | GEO

Basal in vitro transcriptomes of Mycobacterium tuberculosis complex (MTC) clinical isolates

Project description:This study uses microarray analyses to examine baseline gene expression profiles for Mycobacterium tuberculosis complex clinical isolates relative to reference strain CDC1551 during log phase growth in vitro in 7H9 broth. For this in vitro analyses, log-phase mycobacteria in starter cultures grown to mid-log from frozen stocks were inoculated into 7H9-OADC medium in 25-cm2 vented flasks at an OD of ~0.05 and grown without shaking for ~1 week to an OD of ~0.5-0.6.

2010-07-09 | GSE21111 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data